MASTERINVEST Kapitalanlage GmbH Sells 21,058 Shares of Boston Scientific Corporation $BSX

MASTERINVEST Kapitalanlage GmbH lessened its holdings in Boston Scientific Corporation (NYSE:BSX) by 34.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 40,235 shares of the medical equipment provider’s stock after selling 21,058 shares during the quarter. MASTERINVEST Kapitalanlage GmbH’s holdings in Boston Scientific were worth $2,525,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in BSX. Renaissance Group LLC purchased a new position in Boston Scientific in the 4th quarter worth approximately $28,064,000. Rathbones Group PLC boosted its stake in shares of Boston Scientific by 20.9% during the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after purchasing an additional 477,680 shares during the period. Tounjian Advisory Partners LLC bought a new position in shares of Boston Scientific in the fourth quarter worth approximately $1,477,000. Waycross Partners LLC bought a new position in shares of Boston Scientific in the fourth quarter worth approximately $2,384,000. Finally, Union Bancaire Privee UBP SA increased its stake in shares of Boston Scientific by 15.0% in the fourth quarter. Union Bancaire Privee UBP SA now owns 248,497 shares of the medical equipment provider’s stock worth $23,417,000 after buying an additional 32,425 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Down 4.4%

NYSE BSX opened at $42.71 on Wednesday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a twelve month low of $42.25 and a twelve month high of $109.50. The firm has a market capitalization of $63.48 billion, a PE ratio of 17.87, a P/E/G ratio of 0.85 and a beta of 0.58. The stock’s 50 day moving average is $48.88 and its 200 day moving average is $66.76.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its board has authorized a stock repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

BSX has been the subject of a number of recent analyst reports. Oppenheimer set a $90.00 price target on shares of Boston Scientific in a report on Thursday, April 23rd. Mizuho cut their price target on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a report on Monday, April 13th. Evercore set a $65.00 price objective on shares of Boston Scientific in a research report on Monday, July 6th. Royal Bank Of Canada lowered their price objective on shares of Boston Scientific from $100.00 to $85.00 and set an “outperform” rating for the company in a research note on Monday. Finally, Needham & Company LLC cut their target price on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $80.72.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Boston Scientific’s stock fell in the latest session even as the broader market gained, signaling investors are rotating away from the name or reacting to company-specific concerns. Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
• Negative Sentiment: The company initiated several voluntary Class II recalls of CRE and CRE Pro Wireguided endoscopy devices worldwide after potential sterile breaches in packaging, affecting tens of thousands of units and raising quality-control and regulatory risk concerns. Are Boston Scientific’s (BSX) Sterile-Packaging Recalls Reframing the Narrative on Quality and Regulatory Risk?
• Neutral Sentiment: Royal Bank of Canada lowered its price target on BSX to $85 from $100, but kept an “outperform” rating, suggesting the long-term view remains constructive despite recent pressure. Boston Scientific price target lowered by Royal Bank Of Canada
• Neutral Sentiment: Boston Scientific was also mentioned in a market piece highlighting large-cap and sub-$50 stocks, but the item did not include any new company-specific catalyst. 1 Large-Cap Stock with Exciting Potential and 2 We Turn Down

Insider Buying and Selling

In other Boston Scientific news, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Habiger bought 2,250 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 9,800 shares of company stock worth $554,012 in the last three months. 0.34% of the stock is owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.